1. Home
  2. WSHP vs LUNG Comparison

WSHP vs LUNG Comparison

Compare WSHP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WeShop Holdings Limited Class A Ordinary Shares

WSHP

WeShop Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$6.32

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.53

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSHP
LUNG
Founded
2021
1995
Country
British Virgin Islands
United States
Employees
20
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.8M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WSHP
LUNG
Price
$6.32
$1.53
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
619.9K
592.7K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$4.62
$1.13
52 Week High
$250.00
$3.88

Technical Indicators

Market Signals
Indicator
WSHP
LUNG
Relative Strength Index (RSI) 46.80 57.76
Support Level $4.91 $1.22
Resistance Level $7.88 $1.67
Average True Range (ATR) 1.28 0.12
MACD 0.20 0.02
Stochastic Oscillator 24.96 90.48

Price Performance

Historical Comparison
WSHP
LUNG

About WSHP WeShop Holdings Limited Class A Ordinary Shares

WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: